| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0002-9343(99)00067-4 |
| P8608 | Fatcat ID | release_vpj6a45ifveabopbtt5uhgku7m |
| P698 | PubMed publication ID | 10335726 |
| P2093 | author name string | Kohno M | |
| Kano H | |||
| Minami M | |||
| Yoshikawa J | |||
| Yasunari K | |||
| Yokokawa K | |||
| Hanehira T | |||
| P2860 | cites work | Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro | Q28570955 |
| An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels | Q34262228 | ||
| Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells | Q34571434 | ||
| Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation | Q35817405 | ||
| PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1) | Q40421372 | ||
| Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial | Q45098556 | ||
| The presence of brain natriuretic peptide of 12,000 daltons in porcine heart | Q45285348 | ||
| A new natriuretic peptide in porcine brain | Q48100804 | ||
| Accelerated secretion of brain natriuretic peptide from the hypertrophied ventricles in experimental malignant hypertension | Q48540754 | ||
| Brain natriuretic peptide as a cardiac hormone in essential hypertension | Q48571955 | ||
| Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertension. | Q51027011 | ||
| Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. | Q52375631 | ||
| Relation of Left Ventricular Mass and Geometry to Morbidity and Mortality in Uncomplicated Essential Hypertension | Q52455174 | ||
| Some statistical methods useful in circulation research. | Q52759617 | ||
| Deletion polymorphism in angiotensin-converting enzyme gene associated with parental history of myocardial infarction | Q57606111 | ||
| Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction | Q57606113 | ||
| Association between a Deletion Polymorphism of the Angiotensin-Converting-Enzyme Gene and Left Ventricular Hypertrophy | Q58363977 | ||
| Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies | Q68053927 | ||
| Measurement of left ventricular wall thickness and mass by echocardiography | Q68488410 | ||
| Mistyping of the human angiotensin-converting enzyme gene polymorphism: frequency, causes and possible methods to avoid errors in typing | Q71666917 | ||
| Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies | Q71953141 | ||
| Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism | Q72034083 | ||
| Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme | Q72282330 | ||
| Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor | Q72582719 | ||
| ACE gene typing | Q72672643 | ||
| DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy | Q72893483 | ||
| Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts | Q72961588 | ||
| Deletion polymorphism of angiotensin-converting enzyme gene and left ventricular hypertrophy in southern Italian patients | Q73028205 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | left ventricular hypertrophy | Q1628627 |
| P304 | page(s) | 544-549 | |
| P577 | publication date | 1999-05-01 | |
| P1433 | published in | American Journal of Medicine | Q2842959 |
| P1476 | title | Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors | |
| P478 | volume | 106 |
| Q46635550 | A common haplotype on methylenetetrahydrofolate reductase gene modifies the effect of angiotensin-converting enzyme inhibitor on blood pressure in essential hypertension patients--a family-based association study |
| Q46402111 | A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazep |
| Q44525650 | Association of echocardiographic left ventricular structure with the ACE D/I polymorphism: a meta-analysis |
| Q34609133 | Candidate gene approach for pharmacogenetic studies |
| Q35859028 | Drug-gene interactions between genetic polymorphisms and antihypertensive therapy |
| Q46750954 | Effect of 24-week treatment with telmisartan on myocardial structure and function: relationship to insertion/deletion polymorphism of the angiotensin-converting enzyme gene |
| Q37681549 | Genetic polymorphisms related to the renin-angiotensin-aldosterone system and response to antihypertensive drugs. |
| Q92586755 | Genome-wide meta-analysis of SNP and antihypertensive medication interactions on left ventricular traits in African Americans |
| Q61905260 | Left ventricular hypertrophy and angiotensin-converting enzyme gene polymorphism in renal allograft recipients |
| Q54773501 | Left ventricular size, mass and function in relation to angiotensin-converting enzyme gene and angiotensin-II type 1 receptor gene polymorphisms in patients with coronary artery disease. |
| Q34994915 | PharmGKB summary: very important pharmacogene information for angiotensin-converting enzyme |
| Q78537127 | Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study |
| Q35038056 | Pharmacogenetics in drug development |
| Q37430401 | Pharmacogenetics of cardiovascular drug therapy |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q36326202 | Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy |
| Q35086882 | Pharmacogenomics in heart failure: where are we now and how can we reach clinical application? |
| Q35116095 | Pharmacogenomics of primary hypertension--the lessons from the past to look toward the future |
| Q35090217 | Pharmacogenomics: marshalling the human genome to individualise drug therapy |
| Q46179673 | Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment |
| Q34116582 | Renin-angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases |
| Q37472933 | Role of pharmacogenomics in drug discovery and development |
| Q37416129 | Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease. |
| Q35099147 | Skeletal muscle RAS and exercise performance |
| Q34188516 | The DD-ACE genotype and cardiovascular disease. |
Search more.